Silas Inman

Articles by Silas Inman

Suma Krishnan, founder and chief operating officer of Krystal Biotech

Enrollment has completed for the phase 3 GEM-3 study for beremagene geperpavec for patients with dystrophic epidermolysis bullosa. Topline results are anticipated before the end of 2021.